#Antibody Production Market Forecast

[trendingreportz]

Antibody Production Market - Forecast(2024 - 2030)

 Overview

Antibody Production Market is projected to reach revenue of $22.5 billion by 2025, and is estimated to grow at a CAGR of 12.8% during the forecast period 2019-2025. The Antibody Production market size, in 2018, is $9.7 billion. Antibody production by various biotechnology companies is to make medicines or diagnostic tests. The antibodies are mainly used to develop treatments for cancer and diseases such as arthritis, sclerosis, and others.

Request Sample

Key Takeaways

The market is estimated to grow at a CAGR of 12.8% owing to the rising rate of infectious diseases and increasing investments by biotechnology companies to develop treatment for various chronic diseases.

Companies are adopting various strategic alliances to expand in various regions. Investments in antibody production and research have increased in order to develop treatment for deadly diseases such as cancer.

Cancer treatment is observed to be more effective when multiple methods are used. Treatment methods such as stem cell transplantation along with antibody treatment has improved the survival rate of patients. Advances in biotechnology and antibody production have led to the development of various therapies for common diseases.

Process - Segment Analysis

Downstream processing is having major share by revenue in the owing to the large use of chromatography systems and resins for antibody production.  This process is highly accurate, sensitive and effective, making its use popular for the production of antibodies. 

Inquiry Before Buying

Type - Segment Analysis

Main types of antibodies produced are monoclonal and polyclonal antibodies. Monoclonal antibodies are clones of the parent cell and Polyclonal antibodies are made from different cells. Monoclonal antibodies are dominant segment compared to polyclonal antibodies and have a CAGR of 11.2%. They are having more demand for treatment of infections, cancer, and other chronic diseases. A common method of preparation of monoclonal antibodies is using ion exchange chromatography. This is because with this method, the process can be controlled easily and has high capacity or purification capability. Ammonium sulfate precipitation is used for monoclonal and polyclonal isolation.

End-User - Segment Analysis

Pharmaceutical and biotechnological companies are having larger share by end-user segment. This is because of the production of antibodies especially for these companies and due to the high investment for research and development by such companies. 

Schedule a Call

Geography - Segment Analysis

North America accounts for largest Antibody Production market share with 32.3% in 2018. This is owing to the presence of various biotechnology companies present here. Also, the government expenditure for healthcare sector in North America is high. These factors contribute to the growth of the market in this region. However, Asia Pacific will have higher growth rate in the coming years due to supportive regulations and increasing innovations by the companies here.

Drivers – Antibody Production Market

·      Rising rate of chronic diseasesAntibodies protect body by strengthening the immune system. They are used to prevent virus or bacteria related diseases. Antibodies are produced for various infections and are given to people as immunizations. They are also being developed for treatment of cancer and arthritis. Gastric cancer is said to be the second leading cause of global cancer-related deaths. Thus the antibody production will contribute to gastroenterology. The major gastric cancer treatment antibodies include Ramucirumab and Trastuzumab.

·         Increase in expenditure by biotechnology companies

Biosimilars are gaining popularity as they serve the same purpose as the biologic and are also less expensive. With many patent expirations in the coming years, the biotechnology companies are investing in development of biosimilars. They are also increasing expenditure for research and developments for antibody production processes.

Buy Now

Challenges – Antibody Production Market

·         High cost of production

Antibody production requires heavy expense by the companies. Their expenditure and investments for antibody production will be high. The high cost for antibody production will challenge the market.

Antibody Production Industry Outlook

Research & development along with strategic alliances are some of the key strategies adopted by players in the Antibody Production market. Antibody Production Market top 10 companies are Cellab Gmbh, Eppendorf Ag, Integra Bioscience Ag, Merck Kgaa, Pall Corp, Sartorius Ag, Thermo Fisher Scientific, Inc, ProteoGenix, Genentech, Inc. and BIOTEM.

Antibody Production Market Research Scope:

The base year of the study is 2018, with forecast done up to 2025. The study presents a thorough analysis of the competitive landscape, taking into account the market shares of the leading companies. These provide the key market participants with the necessary business intelligence and help them understand the future of the Antibody Production Market. The assessment includes the forecast, an overview of the competitive structure, the market shares of the competitors, as well as the market trends, market demands, market drivers, market challenges, and product analysis. The market drivers and restraints have been assessed to fathom their impact over the forecast period. This report further identifies the key opportunities for growth while also detailing the key challenges and possible threats. 

[mitalipingale]

The Antibody Production Market in 2023 is US$ 18.50 billion, and is expected to reach US$ 49.59 billion by 2031 at a CAGR of 13.10%.

[kenresearch1]

Biosimilars Unleashed: The Future of Healthcare in the US

Buy Now

What is the Size of US Biosimilar Industry?

US Biosimilar Market is expected to grow at a CAGR of ~ % between 2017-2022 and is expected to reach ~USD Bn by 2028. Biosimilars enhance patient access to essential treatments, especially in therapies with high demand, like oncology, by providing more affordable options. Additionally, Growing evidence of biosimilars' comparable efficacy and safety fosters trust among healthcare professionals, driving adoption.

Click here to Download a sample Report

Biosimilars offer cost savings compared to originator biologics, addressing the need for affordable healthcare solutions in the face of rising medical costs. Favorable regulatory frameworks, like the BPCIA, streamline biosimilar approval processes, encouraging manufacturers to invest in development.

Furthermore, The expiration of patents for numerous reference biologics creates opportunities for biosimilar entry, leading to increased competition and market expansion. Pharmaceutical companies are investing in biosimilar R&D and production, expanding the pipeline and market availability. Supportive healthcare policies and reimbursement models incentivize biosimilar adoption, creating a favorable environment for market growth.

US Biosimilar Market by drug class

The US Biosimilar market is segmented by Monoclonal Antibodies, Recombinant Hormones, Immunomodulators, Anti-inflammatory agents and Others. Based on drug class, Monoclonal Antibodies segment dominates the bio similar market in 2022.

Monoclonal antibodies have diverse applications across various therapeutic areas. From cancer treatment to autoimmune diseases, biosimilar Mabs addressed a wide range of medical needs, leading to a broad and growing market. Biosimilars, with their potential for cost savings while maintaining comparable efficacy and safety, gained significant attention as viable alternatives.

US Biosimilar Market by application

In US Biosimilar market, they are segmented by application into Oncology, Blood disorders, Chronic diseases and autoimmune conditions and Others. On the basis of application, Oncology segment was the dominant in 2022.

The increasing prevalence of cancer and the high cost of traditional biologics used in oncology treatment have created a strong incentive for the adoption of biosimilars. Biosimilars offer the potential to provide similar therapeutic outcomes at a lower cost, making them an attractive option for both healthcare providers and patients.

Additionally, the rigorous clinical trials and regulatory processes that biosimilars undergo to gain approval provide reassurance to healthcare professionals and patients regarding their safety and efficacy. This has led to increased acceptance and adoption of biosimilars in oncology.

US Biosimilar by Region

The US Biosimilar market is segmented by Region into North, East, West and South. In 2022, the dominance region is North region in US Biosimilar market.

The North region benefits from a concentration of healthcare providers and academic institutions that are at the forefront of adopting and integrating biosimilars into their treatment protocols. These institutions are more likely to have the expertise to evaluate and incorporate biosimilars effectively, driving their adoption among healthcare professionals and patients.

Click here to Download a Custom Report

Competition Scenario in US Biosimilar Market

The US biosimilar market has witnessed an evolving competitive landscape, with several key players competing for market share. Prominent pharmaceutical companies such as Amgen, Pfizer, Sandoz (Novartis), and Boehringer Ingelheim have been actively involved in developing and marketing biosimilar products. These established players have utilized their expertise in biologics and significant resources to navigate the regulatory landscape and compete effectively.

The competition in the US biosimilar market is characterized by a balance between established pharmaceutical giants and emerging biotech companies. While the major players possess the advantage of resources and experience, smaller biotech firms are also contributing to the market with innovative approaches and niche biosimilar offerings.

What is the Expected Future Outlook for the Overall US Biosimilar Market?

The US Biosimilar market was valued at USD ~Million in 2022 and is anticipated to reach USD ~ Billion by the end of 2028, witnessing a CAGR of ~% during the forecast period 2022- 2028. The US biosimilar market is likely to experience significant growth in the coming years, driven by several factors. Biosimilars are biologic drugs that are highly similar to already approved reference biologics. They offer potential cost savings, increased competition, and improved patient access to crucial treatments.

Firstly, the regulatory environment is becoming more favorable for biosimilars. The Biologics Price Competition and Innovation Act (BPCIA) established a pathway for biosimilar approval in the US, allowing for a smoother regulatory process. As more biosimilars receive approval, competition in the market is expected to intensify.

Secondly, patents for several blockbuster biologics are expiring or have already expired. This creates opportunities for biosimilar manufacturers to enter the market with more affordable alternatives, offering healthcare systems and patients a choice in treatment options.

Thirdly, as healthcare costs continue to rise, biosimilars present an attractive solution for reducing expenses. Their potential to offer cost savings without compromising therapeutic efficacy could lead to increased adoption by healthcare providers, insurers, and patients alike.

Physician and patient education are crucial, as misconceptions about biosimilars' safety and effectiveness might hinder their adoption. Additionally, legal and market access barriers, including patent litigation and complex distribution systems, could slow down the growth of the biosimilar market.

The biosimilar market witness consolidation as larger pharmaceutical companies acquire or partner with smaller biotech firms to bolster their biosimilar portfolios. This will lead to more resources being devoted to biosimilar development and marketing. Changes in healthcare policies, such as reimbursement models and value-based care initiatives, can influence the biosimilar market's growth. Favourable policies that incentivize biosimilar adoption drives their market growth.

[marketanalysisdata]

Squalene Industry - Technologies, Applications, Verticals, Strategies & Forecast 2030

The global squalene market was valued at USD 149.4 million in 2023 and is projected to expand at a compound annual growth rate (CAGR) of 10.9% from 2024 to 2030. The increasing use of natural ingredients in personal care and cosmetic products is a primary driver behind this growth. Squalene, a natural organic compound, is highly valued in these industries due to its translucency, minimal odor, and strong moisturizing properties. These characteristics make it one of the most widely used emollients in skincare. Moreover, squalene’s non-toxic nature has further expanded its applications, making it ideal for use in various personal care products. In cosmetics, squalene oil is especially valued for its role in combating free radicals that damage skin cells and accelerate aging.

The European Union has banned shark oil-based products in cosmetics, which has pushed manufacturers to seek plant-based and synthetic alternatives for squalene production. Concern over shark population decline and the environmental impact of harvesting shark oil has led to increased demand for plant-derived squalene, primarily extracted from sources like olive oil, rice bran, and amaranth oil. Currently, about 65% of the world’s olive oil is produced, consumed, and exported within the European Union, making it a key region for squalene derived from plant-based oils.

Squalene-based adjuvants have been used in influenza vaccines for over 20 years due to their capacity to improve immune response, boost antibody production, and allow for lower doses of the main antigen. This ingredient has been widely recognized for its role in health emergencies, such as influenza outbreaks, due to its effectiveness as an immune enhancer. The COVID-19 pandemic further underscored its utility, as animal-derived squalene was included in COVID-19 vaccines for its immunity-boosting properties. Companies like GlaxoSmithKline (GSK) have established partnerships with other firms, including Sanofi S.A. and CureVac N.V., to facilitate the use of squalene in vaccine production.

Gather more insights about the market drivers, restrains and growth of the Squalene Market

Regional Insights:

Asia Pacific Squalene Market Trends:

Asia Pacific is anticipated to witness significant market growth due to the region’s access to raw materials, lower labor costs, reduced manufacturing costs, and the expansion of industries such as personal care, cosmetics, pharmaceuticals, nutraceuticals, and food and beverages. Countries like India, China, and Japan, which are abundant in raw materials like shark liver oil and olive oil, are emerging as leading producers of squalene for the market.

Europe Squalene Market Trends:

Europe led the squalene market in 2023 with a revenue share exceeding 32.8%, followed closely by the Asia Pacific region. The high share of the European market is largely due to the extensive production of olive oil, which is a primary plant-based source of squalene. Demand for squalene in Europe is particularly high in key economies like Germany, France, the UK, Italy, and Spain. Among European nations, Spain holds a significant portion of the region’s olive groves, which positions it as a major supplier for plant-based squalene. Consequently, European squalene manufacturers are shifting away from shark-based squalene toward plant-based sources.

France

In France, the pharmaceutical industry is notably influential in this market shift. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), the pharmaceutical sector in France had one of the largest R&D budgets in 2021, with R&D spending representing 9.8% of total pharmaceutical revenue. Pharmaceutical companies in France are increasingly investing in research and development focused on creating eco-friendly medicines that utilize bio-based ingredients, a trend that is expected to increase the demand for plant-based squalene in the country’s pharmaceutical industry over the forecast period.

Germany

Germany also demonstrates strong demand for plant-based squalene. In 2020, the country imported approximately 85 tons of olive oil, driven by rising health-consciousness among consumers and the preference for plant-derived ingredients across various sectors. Major companies like L’Oréal in Germany have transitioned from animal-based to plant-based squalene in their formulations, aligning with consumer demand for sustainable and eco-friendly products.

Browse through Grand View Research's Category Food Additives & Nutricosmetics Industry Research Reports.

The global glutamic acid market size was valued at USD 12.55 billion in 2024 and is projected to grow at a CAGR of 8.6% from 2025 to 2030.

The global stearic acid market size was valued at USD 11.24 billion in 2023 and is projected to grow at a CAGR of 5.2% from 2024 to 2030.

Key Companies & Market Share Insights:

The squalene market is highly fragmented and competitive, with major players concentrated in Europe and North America. However, numerous smaller players operate in the Asia Pacific region, where they benefit from proximity to raw materials, particularly shark liver oil and olive oil, which are essential for squalene production.

To extend their reach, major players are adopting partnership strategies. By collaborating with companies in different regions, they can leverage established networks to distribute their products more broadly. For example, in May 2023, Amyris announced a partnership with Croda International Plc. This collaboration aims to supply pharmaceutical-grade squalene for use in vaccine adjuvants, enhancing immune response. Such partnerships demonstrate the strategic moves by leading companies to expand their market presence while meeting the growing demand for high-quality squalene in various applications, from personal care to pharmaceuticals.

Key Squalene Companies:

Amyris, Inc.

Sophim SAS

Henry Lamotte Oils GmbH

efpbiotek

Vestan Limited

Kuraray Co., Ltd.

Croda International Plc

AASHA BIOCHEM

Arbee

Oleicfat, s.l.

Kishimoto Special Liver Oil Co., Ltd.

Order a free sample PDF of the Squalene Market Intelligence Study, published by Grand View Research.

[marketprofessional]

Tissue Diagnostics Market Size, Share & Growth by 2033

Tissue Diagnostics Market Overview The Global Tissue Diagnostics Market has seen continuous development in the past couple of years and is anticipated to grow much further during the forecast period. The exploration introduces a total evaluation of the Tissue Diagnostics Market and contains Future patterns, Current Growth Factors, mindful sentiments, certainties, chronicled information, and factually bolstered and industry-approved market information.

According to Straits Research, the global Tissue Diagnostics market size was valued at USD 5185.23 Million in 2022. It is projected to reach from USD XX Million in 2023 to USD 9375.02 Million by 2031, growing at a CAGR of 6.8% during the forecast period (2023–2031).

After identifying promising candidates, they undergo extensive testing and optimization to enhance their effectiveness, safety, and pharmacokinetic properties. This entire process of Tissue Diagnostics Market may take several years and necessitates collaboration between scientists from diverse fields such as chemistry, biology, and pharmacology. Irrespective of the challenges encountered during Tissue Diagnostics Market, it has the potential to revolutionize lives by providing new treatments for various diseases.

Request Sample Report of Global Tissue Diagnostics Market @ https://straitsresearch.com/report/tissue-diagnostics-market/request-sample

Competitive Analysis The report contains an in-depth analysis of the vendor’s profile, including financial health, business units, key business priorities, SWOT, strategies, and views.

Abbott Laboratories F. Hoffmann-La Roche Ltd Siemens Healthineers bioMerieux Bio SB DiaGenic Enzo Life Sciences, Inc Vitro Sa (Master Diagnóstica) Tissuegnostics Gmbh Abcam Plc Sakura Finetek Japan Co., Ltd Cell Signaling Technology, Inc The vendors have been identified based on the portfolio, geographical presence, marketing & distribution channels, revenue generation, and significant R&D investments.

Request Sample Report of Global Tissue Diagnostics Market @ https://straitsresearch.com/report/tissue-diagnostics-market/request-sample

Vendors across different verticals are planning for high investments in this market, and as a result, the market is expected to grow at an impressive rate in the upcoming years. The key players are adopting various organic and inorganic growth strategies such as mergers & acquisitions, collaboration & partnerships, joint ventures, and a few other strategies to be in a strong position in the global market.

Market Segmentation Analysis The report provides a wide-ranging evaluation of the market, providing in-depth qualitative insights, historical data, and supportable projections along with the assumptions about the Tissue Diagnostics Market size. The projections featured in the report have been derived using proven research methodologies and assumptions based on the vendor’s portfolio, blogs, white papers, and vendor presentations. Thus, the research report represents every side of the Tissue Diagnostics Market and is segmented on the basis of regional markets, offerings, applications, and end-users.

By Technology IHC {Instruments [Slide Staining Systems, Tissue Microarrays, Tissue Processing Systems, Slide Scanners, Other products], Consumables [Reagents, Antibodies, Kits]} In-Situ Hybridization {Instruments, Consumables, Software} Primary and Special Staining Digital Pathology and Workflow {Whole Slide Imaging, Image Analysis Informatics, Information Management System Storage and Communication} Anatomic Pathology {Instruments [Microtomes and Cryostat microtomes, Tissue processors, Automatic strainers, Other products], Consumables [Reagents and Antibodies, Probes and Kits, Others]} By Applications Breast Cancer Prostate Cancer Gastric Cancer Non-Small Cell Lung Cancer Other Cancers By End-User Hospitals Research Laboratories Pharmaceutical Organizations Contract Research Organizations (CROs) Access Detailed Segmentation @ https://straitsresearch.com/report/tissue-diagnostics-market/segmentation

Regional Analysis for Tissue Diagnostics Market The regional analysis offers a comprehensive view of the Tissue Diagnostics Market sales and growth across global and country-level markets. It provides volume and market size data by region, with insights into growth trends in countries like the United States, Canada, Germany, France, China, Japan, and more. The analysis also covers major regions such as North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

Benefits Tissue Diagnostics Market Industry companies to ensure business continuity with powerful protection by constantly checking the report and representing attractive growth opportunities for the companies. Tissue Diagnostics Market handles all the needs of the operators by allowing them to improve their services and concentrate on their core business. Tissue Diagnostics Market Research aims to increase business agility and reduce operational and capital expenditure with improved technology rollouts and capacity planning. The report discusses service types and regions related to this Tissue Diagnostics Market. Further, the report provides details about the major challenges affecting the market growth.

Buy Now: https://straitsresearch.com/buy-now/tissue-diagnostics-market

Other Features of the Report: Provides a thorough analysis of the key strategies with a focus on the corporate structure, R&D methods, localization strategies, production capabilities, sales, and performance in various companies. Provides valuable insights into the product portfolio, including product planning, development, and positioning. Thanks for reading this article; you can also get individual chapter-wise sections or region-wise report versions like North America, Europe, or Asia.

About Us: By Technology IHC {Instruments [Slide Staining Systems, Tissue Microarrays, Tissue Processing Systems, Slide Scanners, Other products], Consumables [Reagents, Antibodies, Kits]} In-Situ Hybridization {Instruments, Consumables, Software} Primary and Special Staining Digital Pathology and Workflow {Whole Slide Imaging, Image Analysis Informatics, Information Management System Storage and Communication} Anatomic Pathology {Instruments [Microtomes and Cryostat microtomes, Tissue processors, Automatic strainers, Other products], Consumables [Reagents and Antibodies, Probes and Kits, Others]} By Applications Breast Cancer Prostate Cancer Gastric Cancer Non-Small Cell Lung Cancer Other Cancers By End-User Hospitals Research Laboratories Pharmaceutical Organizations Contract Research Organizations (CROs) > StraitsResearch.com is a leading research and intelligence organization, specializing in research, analytics, and advisory services along with providing business insights & research reports.

Contact Us: Email: sales@straitsresearch.com Website: https://straitsresearch.com/

[insightfulblogz]

Downstream Processing Market Size, Latest Trends, Share, Growth Analysis, and Forecast 2032

Downstream processing is a crucial phase in biopharmaceutical production, focusing on the purification, separation, and refinement of biologically-derived products. Following upstream production, downstream processing ensures that biomolecules, such as proteins, enzymes, and antibodies, are extracted and purified to meet stringent quality standards. This multi-step process is essential in producing pharmaceuticals, vaccines, and biologics, as it guarantees product purity, safety, and efficacy. Downstream processing is integral to biomanufacturing, supporting the delivery of high-quality products to meet growing global healthcare demands.

The Downstream Processing Market Size was valued at USD 35.89 billion in 2023, and is expected to reach USD 109.78 billion by 2031 and grow at a CAGR of 15% over the forecast period 2024-2031.

Future Scope

The future of downstream processing lies in advancements that streamline workflows, reduce production costs, and increase yields. Innovations such as continuous processing and single-use technologies are gaining momentum, offering scalable solutions that improve efficiency. Furthermore, integration with advanced analytics and automated control systems is expected to enhance process control and consistency, allowing for real-time quality monitoring. These developments are vital for addressing the rising demand for biopharmaceuticals while maintaining high standards and regulatory compliance.

Trends

Current trends in downstream processing include the adoption of single-use systems, which reduce cross-contamination risks and streamline cleaning procedures, and the shift toward continuous processing, which allows for uninterrupted production. Advanced purification techniques, such as membrane filtration and affinity chromatography, are also becoming standard practice, enabling faster and more efficient product refinement. Additionally, there is a strong focus on integrating digital monitoring and control systems to optimize every stage of the process.

Applications

Downstream processing is applied in the production of vaccines, therapeutic antibodies, hormones, and other biologic drugs. It is crucial in purifying cell cultures and separating target biomolecules from complex mixtures. This process is also used in diagnostics, gene therapy, and recombinant protein production, where it ensures the safety and efficacy of the final products. Due to its role in refining biologics, downstream processing is essential in meeting the rigorous standards of the pharmaceutical and biotechnology industries.

Key Points

Downstream processing refines biologically-derived products to ensure purity and safety.

Future developments focus on continuous processing, single-use technologies, and automation.

Trends include advanced purification techniques and digital monitoring systems.

Essential in producing vaccines, biologics, diagnostics, and gene therapies.

Plays a crucial role in biopharmaceutical production to meet regulatory standards.

Conclusion

Downstream processing is the backbone of biopharmaceutical production, enabling the industry to deliver safe, effective, and high-quality biologics. As technological advancements drive efficiency and scalability, downstream processing will continue to support the growth of biomanufacturing, facilitating the rapid development and production of vital therapeutics. This essential process stands at the forefront of innovation in biopharmaceuticals, ensuring the healthcare sector meets the demands for advanced and accessible treatments.

[marketstudyreport]

Biopreservation Market Competitive Landscape and Industry Analysis 2030

The global biopreservation market was valued at USD 2.18 billion in 2022, and it is expected to grow at an impressive compound annual growth rate (CAGR) of 28.30% from 2023 to 2030. This growth is driven by various factors, including extensive applications in healthcare settings like hospitals and laboratories, increased funding from both government and private entities, and advancements in research and development, particularly in the development of new products. For instance, BioLife Solutions introduced a new high-capacity controlled freezer in April 2021, aimed at supporting the cell and gene therapy sector. This addition helped the company expand its product range within biopreservation. The COVID-19 pandemic initially posed challenges for the industry, with disruptions in supply chains, shortages of raw materials, and slowdowns in research activities. However, it also accelerated interest and investment in biologics and vaccine technologies, which ultimately increased the demand for biopreservation solutions, especially for biologics manufacturing and preservation.

Biopreservation is a technique that enables the maintenance of biological materials such as stem cells, DNA, tissues, and organs under controlled temperatures, extending their viability outside their natural environment. Advances in technology, including microarrays, hybrid predictive models, and various API algorithms, are helping to streamline the biopreservation process by reducing its time, cost, and complexity. Additionally, the development of multiplex cellular imaging platforms is expected to boost biopreservation capabilities, especially in supporting disease research. These imaging platforms allow for better analysis of disease progression and facilitate targeted diagnostic and treatment strategies, benefiting fields like cardiology, gynecology, and point-of-care medicine.

Gather more insights about the market drivers, restrains and growth of the Biopreservation Market

Demand for biopreservation has significantly increased in the research and development of biologics across various sectors, including immunotherapy, vaccine production, antibody development, enzyme technology, and bio-manufacturing of chemicals. This surge is partially due to the rising global prevalence of chronic diseases. For example, according to the Centers for Disease Control and Prevention (CDC), cardiovascular diseases and cancer remain among the leading causes of mortality in adults in the United States.

In addition, government and private investments in research and development have spurred significant advancements in the market. There is growing demand for preserving stem cells and creating new biological treatments and products, which has attracted considerable attention and funding from investors. The substantial healthcare spending in this sector is likely to fuel the market's growth in the coming years.

However, the expanding biopreservation market faces some challenges. Key issues include a shortage of skilled professionals, high costs for training, and limited standardization in cybersecurity measures for biopreservation software. These factors may pose risks to market growth by adding complexity and increasing costs for companies operating in this space.

Application Segmentation Insights:

In terms of applications, the biobanking segment held a significant portion of the global market, accounting for 70.65% in 2022. The increasing awareness of stem cell preservation, rising acceptance of sperm and egg banking, and the use of assisted reproductive technologies in animals have all contributed to the segment’s growth. Many pharmaceutical companies are now collaborating with biobanks and hospitals for tissue and biological sample preservation.

The regenerative medicine segment is expected to grow at a higher CAGR of 29.68% during the forecast period, driven by a strong demand for advanced bio-storage techniques. Innovations in specific preservation techniques are likely to further boost growth in this segment over the coming years.

Order a free sample PDF of the Biopreservation Market Intelligence Study, published by Grand View Research.

[farmacuticals]

Exploring Growth Opportunities in the Antibody Fragments Marke

Antibody fragments are engineered components derived from full-length antibodies, designed to retain the specific antigen-binding ability of the original antibody. These fragments are smaller in size, making them advantageous for various applications that require enhanced tissue penetration, reduced immunogenicity, and targeted delivery. Common types of antibody fragments include Fab (antigen-binding fragment), scFv (single-chain variable fragment), and F(ab')2 fragments, each with unique properties tailored for different uses. Due to their smaller size, antibody fragments can often be produced using microbial systems, allowing for cost-effective and scalable production. The versatility and reduced size of antibody fragments have expanded their use in diagnostics, therapeutic applications, and research, which has led to their increasing adoption across these sectors.

The market for antibody fragments was projected to be worth 7.81 billion USD in 2022 based on MRFR analysis. The market for antibody fragments is anticipated to increase from 9.01 billion US dollars in 2023 to 32.4 billion US dollars in 2032. Over the course of the forecast period (2024-2032), the antibody fragments market is anticipated to develop at a CAGR of approximately 15.28%.

Antibody Fragments Size

The compact size of antibody fragments provides a substantial advantage in medical and research applications. Compared to full-length antibodies, which typically have a molecular weight of around 150 kDa, antibody fragments are significantly smaller. For example, Fab fragments have a molecular weight of about 50 kDa, and scFv fragments are even smaller, generally around 25-30 kDa. This smaller size allows for improved tissue penetration, making them ideal for targeting cells in areas where full-sized antibodies may struggle to access. The reduced size also results in faster blood clearance rates, enhancing their effectiveness in targeted therapies and imaging techniques. Overall, the size of antibody fragments plays a pivotal role in their functionality and application scope.

Antibody Fragments Share

The antibody fragments market is steadily growing, capturing a significant share of the antibody and protein engineering markets. Increasing demand for targeted therapies, especially in oncology, infectious diseases, and autoimmune conditions, has contributed to the market’s expansion. The antibody fragments share in the biopharmaceutical industry reflects a rising preference for engineered and more cost-effective therapeutic solutions. Research laboratories, hospitals, and biopharmaceutical companies are among the primary end-users, leveraging antibody fragments for applications ranging from therapeutic research to diagnostic assays. As more research highlights the unique advantages of antibody fragments over traditional antibodies, the market share is expected to continue increasing, further establishing antibody fragments as a valuable segment in the biopharmaceutical industry.

Antibody Fragments Analysis

Comprehensive antibody fragments analysis offers valuable insights into current trends, growth drivers, challenges, and technological advancements. Market analysts evaluate factors such as demand in therapeutic and diagnostic applications, production costs, and technological innovations. The antibody fragments analysis typically highlights the growing trend towards antibody-based biologics, focusing on the benefits of smaller antibody forms, such as reduced immunogenicity and enhanced tissue penetration. Furthermore, advancements in protein engineering and genetic engineering are fostering the development of next-generation antibody fragments with improved stability, specificity, and affinity. This detailed analysis helps industry stakeholders, researchers, and investors understand the potential and limitations of antibody fragments, guiding their decision-making processes and future strategies.

Antibody Fragments Trends

Several notable antibody fragments trends are shaping the future of the biopharmaceutical industry. One key trend is the increased investment in R&D to develop more effective antibody fragment-based therapeutics. The use of antibody fragments in oncology has particularly gained momentum, as these fragments can selectively target cancer cells while minimizing damage to healthy tissues. Another trend is the shift toward the production of antibody fragments using microbial and cell-free systems, reducing production time and cost. Furthermore, the rise of personalized medicine is creating demand for customized antibody fragments tailored to individual patient needs. These trends underscore the importance of antibody fragments in evolving medical research and therapy approaches.

Reasons to Buy the Reports on Antibody Fragments

Market Insights: Gain a deep understanding of current market dynamics, including growth drivers, challenges, and competitive landscape.

Strategic Planning: Use data from the report to develop effective business strategies tailored to the antibody fragments market.

Technological Advancements: Learn about recent innovations and emerging trends in antibody fragment development, from production methods to therapeutic applications.

Investment Opportunities: Identify promising areas for investment, especially in emerging therapeutic applications and production technologies.

Informed Decision-Making: Leverage comprehensive market analysis to make informed decisions in product development, marketing, and distribution.

Recent Developments in Antibody Fragments

Recent development in antibody fragments technology has focused on enhancing specificity, stability, and affinity for target antigens. For instance, breakthroughs in genetic engineering have led to the creation of bispecific antibody fragments that can simultaneously target two different antigens, improving therapeutic efficacy. Advances in phage display technology have also accelerated the screening and selection process for high-affinity fragments. Furthermore, developments in manufacturing have introduced efficient cell-free production methods, making antibody fragment production faster and more cost-effective. These advancements position antibody fragments as a powerful tool in targeted therapies, immunotherapies, and diagnostic applications. As research and development continue to progress, the versatility and potential of antibody fragments in biopharmaceutical applications are expected to expand significantly.

Related reports:

veterinary chemistry analyzer market

veterinary endoscope market

medical clothing market

Top of Form

Bottom of Form

[shubhampawrainfinium]

Immuno-oncology: Revolutionizing Cancer Treatment from Within

The global immuno-oncology market is experiencing remarkable growth and is projected to significantly expand over the forecast period from 2022 to 2028. According to the report, the market was valued at over USD 18 billion in 2022 and is anticipated to reach approximately USD 50 billion by 2028, reflecting a robust compound annual growth rate (CAGR) of nearly 18%.

What is Immuno-Oncology?

Immuno-oncology is a revolutionary approach in cancer treatment that harnesses the body’s immune system to recognize and destroy cancer cells. This innovative field utilizes various strategies, including monoclonal antibodies, immune checkpoint inhibitors, cancer vaccines, and adoptive cell transfer therapies, to enhance the immune response against tumors.

Get Sample pages of Report: https://www.infiniumglobalresearch.com/reports/sample-request/41117

Market Dynamics and Growth Drivers

Several factors are driving the growth of the immuno-oncology market:

Rising Cancer Incidence: The increasing prevalence of various cancers worldwide is a significant driver for the immuno-oncology market. As the global population ages and lifestyle-related cancer risk factors rise, the demand for effective cancer treatments is growing.

Advancements in Research and Development: Significant investments in R&D by pharmaceutical companies have led to the discovery of novel immunotherapeutic agents. Continuous innovation in drug development and clinical trials is expanding the range of treatment options available to patients.

Positive Clinical Outcomes: Immuno-oncology therapies have demonstrated promising clinical outcomes, particularly in challenging cancer types such as melanoma, lung cancer, and bladder cancer. The ability of these therapies to provide durable responses has garnered attention from oncologists and patients alike.

Regulatory Approvals: The increasing number of approvals for immuno-oncology products by regulatory bodies, including the FDA and EMA, is facilitating market growth. Newly approved therapies are enhancing treatment options and driving adoption in clinical settings.

Growing Awareness and Acceptance: As healthcare providers and patients become more aware of the benefits of immunotherapy, there is a growing acceptance of these treatments in standard oncology practice, contributing to market expansion.

Regional Analysis

North America: North America dominates the immuno-oncology market, primarily driven by the presence of leading pharmaceutical companies, extensive R&D activities, and high healthcare expenditure. The U.S. market benefits from a robust regulatory framework and a high prevalence of cancer cases.

Europe: The European market is experiencing significant growth due to increasing cancer awareness, improved access to healthcare, and a strong focus on innovative cancer therapies. European countries are actively investing in immuno-oncology research and development.

Asia-Pacific: The Asia-Pacific region is anticipated to witness the fastest growth in the immuno-oncology market, driven by a rising patient population, increasing healthcare expenditure, and advancements in healthcare infrastructure. Countries like China and India are emerging as significant players in the immuno-oncology landscape.

Latin America: The Latin American market is expanding, driven by increasing investments in healthcare and rising awareness of immunotherapy options. Governments are also focusing on improving cancer care access in the region.

Middle East and Africa: The immuno-oncology market in the Middle East and Africa is growing, although it faces challenges related to healthcare access and affordability. However, rising investments in healthcare infrastructure are expected to drive future growth.

Competitive Landscape

The global immuno-oncology market is competitive, with several key players leading the charge:

Bristol-Myers Squibb: A pioneer in immuno-oncology, known for its leading checkpoint inhibitors like Opdivo (nivolumab) and Yervoy (ipilimumab).

Merck & Co.: Recognized for its PD-1 inhibitor Keytruda (pembrolizumab), which has shown effectiveness across multiple cancer types.

Roche: A strong player in the immuno-oncology space with its antibody therapies, including Tecentriq (atezolizumab).

Novartis: Engaged in developing CAR-T cell therapies and checkpoint inhibitors to advance the immuno-oncology landscape.

AstraZeneca: Known for its innovative oncology pipeline, including drugs like Imfinzi (durvalumab) and Lynparza (olaparib).

Report Overview : https://www.infiniumglobalresearch.com/reports/global-immuno-oncology-market

Challenges and Opportunities

Despite its promising growth trajectory, the immuno-oncology market faces challenges such as high treatment costs, varying patient responses, and potential side effects associated with therapies. Additionally, the complexity of the immune system poses challenges in identifying biomarkers for patient selection and optimizing treatment protocols.

However, there are numerous opportunities for growth in this market. The development of combination therapies that synergize immunotherapy with traditional treatments (e.g., chemotherapy and radiation) presents a promising avenue for enhancing patient outcomes. Furthermore, ongoing research into personalized medicine and targeted immunotherapies is expected to create new growth opportunities in the market.

Conclusion

The global immuno-oncology market is poised for remarkable growth, projected to expand from over USD 18 billion in 2022 to approximately USD 50 billion by 2028, with a CAGR of nearly 18%. Factors such as rising cancer incidence, advancements in research and development, and increasing acceptance of immunotherapy are driving this growth. As the field continues to evolve, immuno-oncology will play a pivotal role in transforming cancer treatment and improving patient outcomes worldwide.

Discover More of Our Reports

United States Eyewear Market

United States Biopreservation Market

[jayanthitbrc]

Global Immunotoxin Market Analysis 2024: Size Forecast and Growth Prospects

The immunotoxin global market report 2024from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.

Immunotoxin Market, 2024report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.

Market Size - The immunotoxin market size has grown strongly in recent years. It will grow from $55.94 billion in 2023 to $60.97 billion in 2024 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to the discovery of target antigens, advancements in monoclonal antibody technology, preclinical efficacy studies, clinical trials and regulatory approval, and identification of resistance mechanisms.

The immunotoxin market size is expected to see strong growth in the next few years. It will grow to $86.29 billion in 2028 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to the increasing incidence of cancer, rising demand for natural and organic products, expansion of the cosmetic industry, expansion of R and D financing, and improving healthcare infrastructure. Major trends in the forecast period include precision medicine approach, enhanced targeting strategies, multifunctional immunotoxins, combination therapies, and advancements in monoclonal antibody technology.

Order your report now for swift delivery @ https://www.thebusinessresearchcompany.com/report/immunotoxin-global-market-report

Scope Of Immunotoxin MarketThe Business Research Company's reports encompass a wide range of information, including:

1. Market Size (Historic and Forecast): Analysis of the market's historical performance and projections for future growth.

2. Drivers: Examination of the key factors propelling market growth.

3. Trends: Identification of emerging trends and patterns shaping the market landscape.

4. Key Segments: Breakdown of the market into its primary segments and their respective performance.

5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.

6. Macro Economic Factors: Assessment of broader economic elements impacting the market.

Immunotoxin Market Overview

Market Drivers -The increasing incidence of breast cancer is expected to propel the growth of the immunotoxin market going forward. Breast cancer refers to a type of cancer that forms in the cells of the breast. The rising incidence of breast cancer is primarily due to improved screening, lifestyle changes, and increased life expectancy. Immunotoxins help in breast cancer by targeting and killing cancer cells while sparing healthy cells, reducing side effects associated with traditional chemotherapy. For instance, in 2023 according to the American Cancer Society, a US-based non-profit organization, there were 300,590 new cases of breast cancer reported, showing an increase compared to the 290,560 cases reported in 2022. Therefore, an increasing incidence of breast cancer is driving the growth of the immunotoxin market.

Market Trends - Major companies operating in the immunotoxin market are focused on developing antibody-drug conjugates (ADCs) to enhance the specificity and efficacy of cancer treatment. ADCs are biopharmaceutical medicines that are intended to be used as targeted cancer treatments. Antibody-drug conjugates are made up of an antibody coupled to a cytotoxic medication, enabling targeted drug delivery to cancer cells that express a specific antigen. For instance, in April 2024, Pfizer Inc., a US-based pharmaceutical company, and Genmab A/S, a Denmark-based biotechnology company, received full U.S. Food and Drug Administration (FDA) approval for TIVDAK, a first antibody-drug conjugate designed to treat patients with metastatic or recurrent cervical cancer. The toxic payload of TIVDAK is monomethyl auristatin E, a microtubule-disrupting chemical that causes cell death. This novel mechanism leads to its efficiency in cancer treatment. TIVDAK showed statistically significant increases in overall survival, making it a promising alternative for individuals with recurrent or metastatic cervical cancer.

The immunotoxin market covered in this report is segmented –

1) By Type: Anthrax Based Toxins, Diphtheria Toxin (DT) And Derivatives, Pseudomonas Exotoxin (PE) And Derivatives, Ribosome Inactivating Proteins Based Immunotoxins, Ribonucleases-Based Immunotoxins, Other Types 2) By Application: Solid Tumors, Leukemias, Other Applications 3) By End User: Hospitals And Clinics, Cancer And Radiation Therapy Centers, Research Labs, Other End-Users

Get an inside scoop of the immunotoxin market, Request now for Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=15828&type=smp

Regional Insights - North America was the largest region in the immunotoxin market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunotoxin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Key Companies - Major companies operating in the immunotoxin market are Pfizer Inc., Roche Holding AG, AbbVie Inc., Bayer AG, Bristol Myers Squibb, Thermo Fisher Scientific Inc., AstraZeneca plc, Merck KGaA, BioNTech SE, Ipsen Pharma, Seagen Inc., Orion Corporation, GenScript, Cytek Biosciences, MacroGenics Inc., Sutro Biopharma Inc., Sorrento Therapeutics Inc., Innate Pharma Inc., Cayman Chemical, ImmunoGen Inc., Mersana Therapeutics, Molecular Templates Inc., Celldex Therapeutics, CytImmune Sciences Inc., Enzo Life Sciences Inc.

Table of Contents 1. Executive Summary 2. Immunotoxin Market Report Structure 3. Immunotoxin Market Trends And Strategies 4. Immunotoxin Market – Macro Economic Scenario 5. Immunotoxin Market Size And Growth ….. 27. Immunotoxin Market Competitor Landscape And Company Profiles 28. Key Mergers And Acquisitions 29. Future Outlook and Potential Analysis 30. Appendix

Contact Us: The Business Research Company Europe: +44 207 1930 708 Asia: +91 88972 63534 Americas: +1 315 623 0293 Email: info@tbrc.info

Follow Us On: LinkedIn: https://in.linkedin.com/company/the-business-research-company Twitter: https://twitter.com/tbrc_info Facebook: https://www.facebook.com/TheBusinessResearchCompany YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ Blog: https://blog.tbrc.info/ Healthcare Blog: https://healthcareresearchreports.com/ Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[credenceresearchdotblog]

The Chromatography Resins Market is projected to grow from USD 2,645.5 million in 2024 to approximately USD 4,345.51 million by 2032, at a compound annual growth rate (CAGR) of 6.40%. The chromatography resins market has grown significantly in recent years, with applications expanding across pharmaceutical, biotechnology, food, and environmental sectors. Chromatography, a versatile and essential analytical technique, separates compounds in complex mixtures and purifies valuable compounds. Resins, as the critical stationary phase in chromatography, are fundamental to separation processes, making chromatography resins a vital component across industries. The increasing demand for high-purity compounds, especially in drug development, and stringent regulatory standards are fueling market growth.

Browse the full report https://www.credenceresearch.com/report/chromatography-resins-market

Market Overview

The global chromatography resins market has demonstrated substantial growth due to increasing demand from biopharmaceuticals and bioprocessing industries. With applications across ion exchange, affinity, size exclusion, and hydrophobic interaction chromatography, resins serve a pivotal role in both qualitative and quantitative analyses. The global market size for chromatography resins was valued at approximately $2.1 billion in 2023, and it is projected to witness a steady growth rate over the next five years. Key factors driving this growth include the expansion of the pharmaceutical industry, especially in biologics, and rising demand for therapeutic antibodies and vaccines.

Key Drivers

1. Expansion in Pharmaceutical and Biotechnology Sectors Pharmaceutical and biotechnology companies are major consumers of chromatography resins, especially for drug development and production. Chromatography is critical in purifying and analyzing biologics like monoclonal antibodies, gene therapies, and vaccines, requiring high-purity resins to ensure efficacy and safety. With the rise in chronic diseases and the demand for innovative biologic drugs, biopharmaceutical companies are investing heavily in high-quality resin materials for efficient separation and purification.

2. Technological Advancements in Chromatography Techniques Continuous advancements in chromatography techniques, including high-performance liquid chromatography (HPLC) and ultra-performance liquid chromatography (UPLC), have heightened the demand for specialized resins. Enhanced technologies improve the efficiency, speed, and precision of separation, and these innovations are creating new avenues in industries like healthcare and environmental science. Additionally, automation and integration of artificial intelligence (AI) in chromatography are expected to bolster market growth by optimizing processes.

3. Growth in Environmental Testing and Food & Beverage Analysis Environmental and food safety regulations are becoming stricter globally, leading to increased demand for chromatography resins in testing applications. The detection of contaminants, such as pesticides and heavy metals, requires precise chromatography methods. Chromatography resins help achieve reliable and consistent results, making them critical in these sectors. With the rise in consumer demand for food safety and environmental protection, chromatography resins are increasingly utilized in these applications.

Regional Insights

The chromatography resins market shows significant growth potential across different regions, with North America currently holding a substantial share. This dominance is attributed to a strong pharmaceutical and biopharmaceutical presence, stringent regulations, and advanced healthcare infrastructure. Europe follows closely, driven by high regulatory standards and investments in biotechnological research. The Asia-Pacific region, led by China and India, is expected to witness the fastest growth due to expanding pharmaceutical production, increasing government investment in healthcare, and growing food safety concerns.

Competitive Landscape

Major players in the chromatography resins market include GE Healthcare, Merck KGaA, Bio-Rad Laboratories, and Thermo Fisher Scientific. These companies focus on R&D to develop innovative resins that offer higher efficiency and sustainability. Additionally, strategic collaborations, acquisitions, and product expansions are common approaches among industry leaders to enhance their market position.

Future Outlook and Challenges

While the chromatography resins market holds promising growth potential, it faces some challenges. High production costs, complex manufacturing processes, and strict regulations can limit smaller companies' ability to compete. However, the rise in personalized medicine, increasing demand for high-purity biomolecules, and the continuous development of next-generation chromatography technologies present significant growth opportunities. The market is anticipated to grow as demand for faster, more efficient, and environmentally friendly resins increases.

Key Player Analysis:

GE Healthcare (Cytiva)

Merck KGaA

Bio-Rad Laboratories, Inc.

Thermo Fisher Scientific, Inc.

Tosoh Corporation

Purolite Corporation

Avantor, Inc.

Pall Corporation (Danaher)

Repligen Corporation

Mitsubishi Chemical Corporation

Segmentations:

By Technique

Hydrophobic Interaction

Ion Exchange

Multi-Modal/Mixed Mode

Affinity

Size Exclusion

Others

By Type

Synthetic Polymers

Natural Polymers

Inorganic Media

By Application

Food & Beverage

Pharmaceutical & Biotechnology

Water & Environmental Analysis

Others

By Region

North America

US

Canada

Mexico

Europe

Germany

France

UK

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Browse the full report https://www.credenceresearch.com/report/chromatography-resins-market

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com

Website: www.credenceresearch.com 

[mordormr]

Exploring the Growth and Innovation in the Biopharmaceuticals Industry

The Biopharmaceuticals Market size is projected to reach a value of USD 401.46 billion in 2024, with expectations to grow to USD 577.87 billion by 2029, reflecting a CAGR of 7.56% over the forecast period from 2024 to 2029.

Market Size and Growth Potential

According to market research, the biopharmaceuticals market is experiencing substantial growth, spurred by a range of factors, including aging populations, increasing prevalence of chronic diseases, and innovations in bio-manufacturing technologies. The shift from traditional small-molecule drugs to complex, large-molecule biopharmaceuticals reflects the market’s evolution. Companies in this sector are investing heavily in research and development (R&D) to bring forward novel treatments that promise better patient outcomes with fewer side effects.

Key therapeutic areas driving the biopharmaceutical market include:

Oncology: Cancer therapies are a primary focus within biopharmaceuticals, as biologics offer new approaches to targeting and treating various cancer types. The use of monoclonal antibodies, for example, has transformed treatment strategies by enabling the immune system to recognize and attack cancer cells more effectively.

Autoimmune Diseases: Treatments for autoimmune disorders such as rheumatoid arthritis, psoriasis, and multiple sclerosis have also advanced with biopharmaceutical solutions, offering patients more effective, targeted relief through biologics that suppress or modulate immune responses.

Rare and Genetic Disorders: Gene and cell therapies represent revolutionary treatment options for rare and genetic disorders, allowing healthcare providers to correct or replace faulty genes directly. These therapies hold immense promise for conditions that previously lacked viable treatment options.

Technological Advances and R&D Investments

The industry’s growth is underpinned by continuous innovation in biotechnology, including advances in gene editing (e.g., CRISPR), next-generation sequencing, and bioprocessing techniques that make production more scalable and cost-effective. Leading companies and research institutions are pouring resources into R&D, resulting in a robust pipeline of promising new therapies. The acceleration of artificial intelligence and machine learning in drug discovery and development processes has also streamlined the identification of potential new drugs, increasing efficiency and success rates.

Conclusion

The biopharmaceuticals industry is poised for continued growth, offering transformative potential for treating and managing complex diseases. As companies leverage biotechnology innovations to create safer and more effective therapies, the market will see expanding opportunities and new applications in healthcare. While challenges remain, the biopharmaceutical sector’s commitment to advancing healthcare solutions marks it as a key player in the future of medicine.

For a detailed overview and more insights, you can refer to the full market research report by Mordor Intelligence https://www.mordorintelligence.com/industry-reports/global-biopharmaceuticals-market-industry  

[kenresearch1]

Top 5 players in US Biosimilar Market

Buy Now

STORY OUTLINE

Pfizer: Excelling in the line of Biosimilar drugs with an experience of more than 10 years with presence in over 180 countries.

Amgen: Making pharmaceutical products with an experience of over 40 years and presence in over 100 countries.

Viartis: Presence in over 165 countries, and making Biosimilar drugs in over 75 markets, this pharmaceutical company is another leading contributor of US Biosimilar market.

Coherus Biosciences: Increasing patient access to cost effective medicines with a Biosimilar drugs experience of 13 years.

Biogen: serving humanity through science with a experiences of more than 40 years in the field of biologics.

According to Ken Research, the US Biosimilar market is anticipated to grow at a CAGR of ~40% in the next five years which currently has a market size of ~USD 9.4 Bn.

The US Biosimilar market is rapidly growing and will be witnessing a significant growth in the next five years.

There are various reasons behind the rapid growth of US Biosimilar market. Some of the major reasons behind the growth of US Biosimilar market include the cost effective nature of Biosimilar drugs, rising geriatric population, rising prevalence of chronic diseases, and growing partnerships between companies to develop Biosimilar drugs.

Various companies and players are contributing to their best efforts in the growth of the US Biosimilar market.

This article aims to put light on the contributions done by the major players towards the growth of the US Biosimilar market.

1.Pfizer

Click to read more about Pfizer

Pfizer is a leading American pharmaceutical company which is operating in the field of generics or original drugs for more than 30 years. But did you know that this pharma not only manufactures biologics but also biosimilar drugs?

Pfizer has been in the business of biosimilar drugs for more than 10 years and have been quite successful as well. With more than 83,000 employees and presence in over 180 countries, this leading pharmaceutical company made almost USD 2 Bn. revenue only from its Biosimilar drugs sale in 2021.

Recently, this pharmaceutical company also collaborated with Samsung in two deals to produce various biosimilar drugs in South Korea. The deal size between these two companies happens to be approximately USD 900 Bn.

The major Biosimilar drugs of this pharmaceutical giant are primarily

ZIRABEV (a Biosimilar of Avastin)

TRAZIMERA (a Biosimilar of Herceptin)

RUXIENCE (a Biosimilar of Rituxan)

RITACRIT (a Biosimilar of Epogen)

NVYEPRIA (a Biosimilar of Neulasta)

NIVESTYM (a Biosimilar of Neupogen)

FILGRASTIM (a Biosimilar of Neupogen).

2.Amgen

Click here to Download a Sample Report

Amgen is another leading American pharmaceutical company which not only makes Biologics or generic drugs but also Biosimilar drugs. This pharmaceutical company has more than 40 years of experience when it comes to pharmaceutical line.

With over 25000 employees and presence in over 100 countries, this pharmaceutical company earned about USD 2 Bn. from their three biosimilar drugs which are reportedly MVASI, KANJITNTI, and AMJEVITA.

This pharma giant has also invested about USD 2 Bn. in the development of Biosimilar drugs.

This pharmaceutical company has made Biosimilar drugs primarily in 4 fields which are General Medicine, Oncology, and Hematology along with, Inflammation.

EPOTEIN ALFA

AMJEVITA

AVSOLA

KANJINTI

MVASI

RIABNI

are the various Biosimilar drugs of Amgen. And, STELARA, EYLEA, SOLIRIS are in their pipeline.

Recently Amgen revealed their Biosimilar report’s 8 version. It revealed a major information which said that the pharmaceutical company saved about USD 10 Bn. through their Biosimilar drugs in the past five years.

3.Viartis

Headquartered in Canonsburg, Pennsylvania, this American pharmaceutical company was founded only in 2020 yet they have achieved massive success in the pharmaceutical products with their revenue being USD 16 ~Bn. in 2022.

With presence in 165 countries and with over 45,000 employees worldwide, this pharmaceutical company makes pharmaceutical products in 10 areas which primarily are Cardiovascular, Dermatology, ophthalmology, Oncology, Gastroenterology, Women’s health, Infectious diseases, Diabetes & Metabolism, Immunology, CNS & Anesthesiology, Respiratory diseases and allergy.

Speaking of their first Biosimilar products, their first ever Biosimilar drug was launched in 2014. They have a variety of Biosimilar drugs which are primarily

TRASTUZUMAB

INSULIN ASPART

PEGFILGRASTIM

INSULIN GLARGINE-YFGN

ADALIMUMAB

BEVACIZUMAB

Their Biosimilar drug Insulin Glargine which is known as SEMGLEE was the first ever interchangeable Biosimilar drug in the United States which was FDA approved.

Their PEGFILGRASTIM also was the first ever FDA approved drug in the United States. They have launched their Biosimilar drugs in over 75 markets worldwide.

4.Coherus Biosciences:

Click here to Ask for a Custom Report

Headquartered in Redwood city, California this American pharmaceutical company earned a revenue of almost USD 211 Mn. In 2022.

With presence in over 55 countries and 300+ employees worldwide, this pharmaceutical company makes products in various areas such as solid tumors, non-small lung cancers, nasopharyngeal carcinoma, small cell lung cancer and hepatocellular carcinoma.

Speaking of their Biosimilar drugs, this pharma has been in the field of creating Biosimilar drugs since 2010 which has given them almost 13 years of experience.

This pharmaceutical company also disclosed that it plans to spend at least USD 1 Tn. on medicines worldwide, out of which at least 40% will be spent on Biosimilar drugs.

Their three major Biosimilar drugs which are also FDA approved include UDENCYA, YUSIMRY, and CIMERLI.

Udencya is a Biosimilar drug of Pegfilgrastim, Yusimry is a Biosimilar drug of Ranibizumab, and Cimerli is a Biosimilar drug of Adalimumab.

5.Biogen

Headquartered in Cambridge, Massachusetts, this American pharmaceutical company earned a revenue of around USD 10 Bn. in 2022.

This company happens to have an experience of more than 40 years when it comes to making pharmaceutical products.

With presence in over 80 countries and more than 9000 employees worldwide, this pharmaceutical company primarily deals in Neurology, Specialized Immunology, Neuropsychiatry, Ophthalmology, and Rare Diseases.

ADUCANUMAB

LECANEMAB

TOFERSEN

ZURANOLONE

LITIFILIMAB

BENAPALI

FLIXABI

IMRALDI

are some of their Biosimilar drugs.

With their Biosimilar drugs, more than 250,000 people have gone on Anti-Tumor Necrosis Factor therapy.

Recently, this pharmaceutical company also made an agreement with Bio-Thera solutions to develop a Biosimilar drug for the treatment of Rheumatoid Arthritis.

[marketanalysisdata]

Biopreservation Market Revenue, Share and Growth Rate to 2030

The global biopreservation market was valued at USD 2.18 billion in 2022, and it is expected to grow at an impressive compound annual growth rate (CAGR) of 28.30% from 2023 to 2030. This growth is driven by various factors, including extensive applications in healthcare settings like hospitals and laboratories, increased funding from both government and private entities, and advancements in research and development, particularly in the development of new products. For instance, BioLife Solutions introduced a new high-capacity controlled freezer in April 2021, aimed at supporting the cell and gene therapy sector. This addition helped the company expand its product range within biopreservation. The COVID-19 pandemic initially posed challenges for the industry, with disruptions in supply chains, shortages of raw materials, and slowdowns in research activities. However, it also accelerated interest and investment in biologics and vaccine technologies, which ultimately increased the demand for biopreservation solutions, especially for biologics manufacturing and preservation.

Biopreservation is a technique that enables the maintenance of biological materials such as stem cells, DNA, tissues, and organs under controlled temperatures, extending their viability outside their natural environment. Advances in technology, including microarrays, hybrid predictive models, and various API algorithms, are helping to streamline the biopreservation process by reducing its time, cost, and complexity. Additionally, the development of multiplex cellular imaging platforms is expected to boost biopreservation capabilities, especially in supporting disease research. These imaging platforms allow for better analysis of disease progression and facilitate targeted diagnostic and treatment strategies, benefiting fields like cardiology, gynecology, and point-of-care medicine.

Gather more insights about the market drivers, restrains and growth of the Biopreservation Market

Demand for biopreservation has significantly increased in the research and development of biologics across various sectors, including immunotherapy, vaccine production, antibody development, enzyme technology, and bio-manufacturing of chemicals. This surge is partially due to the rising global prevalence of chronic diseases. For example, according to the Centers for Disease Control and Prevention (CDC), cardiovascular diseases and cancer remain among the leading causes of mortality in adults in the United States.

In addition, government and private investments in research and development have spurred significant advancements in the market. There is growing demand for preserving stem cells and creating new biological treatments and products, which has attracted considerable attention and funding from investors. The substantial healthcare spending in this sector is likely to fuel the market's growth in the coming years.

However, the expanding biopreservation market faces some challenges. Key issues include a shortage of skilled professionals, high costs for training, and limited standardization in cybersecurity measures for biopreservation software. These factors may pose risks to market growth by adding complexity and increasing costs for companies operating in this space.

Application Segmentation Insights:

In terms of applications, the biobanking segment held a significant portion of the global market, accounting for 70.65% in 2022. The increasing awareness of stem cell preservation, rising acceptance of sperm and egg banking, and the use of assisted reproductive technologies in animals have all contributed to the segment’s growth. Many pharmaceutical companies are now collaborating with biobanks and hospitals for tissue and biological sample preservation.

The regenerative medicine segment is expected to grow at a higher CAGR of 29.68% during the forecast period, driven by a strong demand for advanced bio-storage techniques. Innovations in specific preservation techniques are likely to further boost growth in this segment over the coming years.

Order a free sample PDF of the Biopreservation Market Intelligence Study, published by Grand View Research.

[harshnews]

Melanoma Cancer Diagnostics Market Size, Share, Demand, Future Growth, Challenges and Competitive Analysis

"Global Melanoma Cancer Diagnostics Market – Industry Trends and Forecast to 2030

Global Melanoma Cancer Diagnostics Market, By Product Type (Instruments, Consumables and Accessories, and Others), Test Type (Biomarkers Test, Imaging Test, Biopsy, Fluorescent In Situ Hybridization (FISH) Tests, Comparative Genomic Hybridization (CGH) Tests, Immunohistochemical (IHC) Tests, and Others), End User (Hospitals, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes and Others), Distribution Channel (Direct Tender and Retail Sales) - Industry Trends and Forecast 2030.

Access Full 350 Pages PDF Report @

**Segments**

- **By Type**: The Melanoma Cancer Diagnostics market can be segmented by type into Imaging Tests, Biopsy, Blood Tests, and Dermatoscopy. Imaging tests, such as ultrasound, CT scan, and MRI, help in detecting the presence and spread of melanoma. Biopsy is a crucial diagnostic tool that involves the removal of suspicious cells or tissue for examination. Blood tests like liquid biopsy are emerging as a non-invasive method to detect melanoma by analyzing circulating tumor cells or cell-free DNA. Dermatoscopy, also known as dermoscopy, is a non-invasive technique that allows dermatologists to examine skin lesions for signs of melanoma.

- **By Technology**: The market can also be segmented by technology, including Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), and In Situ Hybridization (ISH). NGS enables precise genetic profiling of melanoma tumors, aiding in personalized treatment strategies. PCR amplifies and detects specific DNA sequences, useful in detecting genetic mutations associated with melanoma. IHC involves using antibodies to identify antigens in melanoma cells, assisting in pathological diagnosis. ISH helps in visualizing specific nucleic acid sequences within melanoma cells for diagnostic purposes.

- **By End-User**: The Melanoma Cancer Diagnostics market can be segmented by end-user into Hospitals, Clinics, Diagnostic Centers, and Research Institutes. Hospitals play a vital role in diagnosing and treating melanoma cases, often equipped with advanced diagnostic technologies. Clinics provide primary care and early diagnosis services for individuals at risk of melanoma or with suspicious skin lesions. Diagnostic centers specialize in conducting various tests and procedures for accurate melanoma detection. Research institutes drive innovation in melanoma diagnostics through clinical trials, new technology development, and academic research.

**Market Players**

- **Abbott Laboratories**: A multinational healthcare company that offers a range of diagnostic solutions, including tests for melanoma cancerAbbott Laboratories is a key player in the Melanoma Cancer Diagnostics market, offering a diverse portfolio of diagnostic solutions that cater to the detection and management of melanoma. As a multinational healthcare company, Abbott leverages its expertise in innovative technologies to develop cutting-edge diagnostic tests that aid in the early detection and precise diagnosis of melanoma cancer. The company's commitment to advancing healthcare through research and development has positioned it as a leading provider of diagnostic solutions for various types of cancers, including melanoma.

In the Melanoma Cancer Diagnostics market, Abbott Laboratories faces significant competition from other industry players who also offer a range of diagnostic tools and technologies for melanoma detection. However, Abbott's strong brand reputation, extensive global presence, and focus on research and development set it apart from competitors. By investing in advanced technologies such as Next-Generation Sequencing (NGS) and Polymerase Chain Reaction (PCR), Abbott can deliver highly accurate and reliable diagnostic solutions that help healthcare professionals in the early detection and personalized treatment of melanoma.

Moreover, Abbott's strategic partnerships with healthcare institutions, research organizations, and key opinion leaders enable the company to stay at the forefront of innovation in melanoma diagnostics. By collaborating with leading experts in the field, Abbott can gain valuable insights into emerging trends, technological advancements, and unmet needs in melanoma cancer diagnosis. This collaborative approach not only enhances Abbott's product development efforts but also strengthens its position as a trusted partner for healthcare providers seeking reliable diagnostic solutions for melanoma.

Furthermore, Abbott Laboratories' strong focus on regulatory compliance, quality assurance, and adherence to global standards ensures that its diagnostic solutions meet the highest level of accuracy and reliability. This commitment to quality control and regulatory compliance instills confidence in healthcare professionals and patients who rely on Abbott's diagnostic tests for the early detection and monitoring of melanoma cancer. By maintaining stringent quality standards and investing in continuous improvement initiatives, Abbott demonstrates its dedication to delivering best-in-class diagnostic solutions for melanoma diagnostics.

In conclusion, Abbott**Global Melanoma Cancer Diagnostics Market**

- **Segments**

**By Type:** The Melanoma Cancer Diagnostics market is segmented by type into various categories such as Imaging Tests, Biopsy, Blood Tests, and Dermatoscopy. Each of these segments plays a crucial role in the early detection and accurate diagnosis of melanoma cancer. Imaging tests like ultrasound and MRI help in visualizing tumor presence and spread, while biopsies provide tissue samples for further examination. Blood tests, including liquid biopsy, offer a non-invasive method to detect melanoma by analyzing circulating tumor cells. Dermatoscopy enables dermatologists to examine skin lesions for signs of melanoma effectively.

**By Technology:** Another crucial segmentation of the Melanoma Cancer Diagnostics market is by technology, incorporating advanced methods like Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), and In Situ Hybridization (ISH). These technologies enable precise genetic profiling of melanoma tumors, detection of specific DNA sequences and genetic mutations, identification of antigens in melanoma cells, and visualization of nucleic acid sequences, respectively. Their application enhances the accuracy and efficiency of melanoma diagnosis and treatment.

**By End-User:** The Melanoma Cancer Diagnostics market is further segmented by end-user, catering to entities such as Hospitals, Clinics, Diagnostic Centers, and Research Institutes. Each of these segments plays a vital role in different stages of melanoma diagnosis and

Highlights of TOC:

Chapter 1: Market overview

Chapter 2: Global Melanoma Cancer Diagnostics Market

Chapter 3: Regional analysis of the Global Melanoma Cancer Diagnostics Market industry

Chapter 4: Melanoma Cancer Diagnostics Market segmentation based on types and applications

Chapter 5: Revenue analysis based on types and applications

Chapter 6: Market share

Chapter 7: Competitive Landscape

Chapter 8: Drivers, Restraints, Challenges, and Opportunities

Chapter 9: Gross Margin and Price Analysis

Key Questions Answered with this Study

1) What makes Melanoma Cancer Diagnostics Market feasible for long term investment?

2) Know value chain areas where players can create value?

3) Teritorry that may see steep rise in CAGR & Y-O-Y growth?

4) What geographic region would have better demand for product/services?

5) What opportunity emerging territory would offer to established and new entrants in Melanoma Cancer Diagnostics Market?

6) Risk side analysis connected with service providers?

7) How influencing factors driving the demand of Melanoma Cancer Diagnostics in next few years?

8) What is the impact analysis of various factors in the Global Melanoma Cancer Diagnostics Market growth?

9) What strategies of big players help them acquire share in mature market?

10) How Technology and Customer-Centric Innovation is bringing big Change in Melanoma Cancer Diagnostics Market?

Browse Trending Reports:

Body Scanner Market Prenatal Genetic Counselling Market Lead Acid Ev Vehicle Market Tuck Top Box Market Hexagonal Boron Nitride Powder Market Erythropoietin Epo Drugs Market Pancreatic Cancer Treatment Market Ionic Liquid Market Oat Bran Market Liquid Sulfur Fertilizers Market Edible Packaging Market Non Gmo Food Market Antenna Market Cervical Intraepithelial Neoplasia Drugs Market Contraceptives Market Triac Market Primary Antibodies Market Breast Implants Accessories Market

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us:

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC : +653 1251 975

Email: corporatesales@databridgemarketresearch.com"

[insightfulblogz]

Low-Pressure Liquid Chromatography Market Growth Statistics and Key Players Insights (2024-2032)

Low-pressure liquid chromatography (LPLC) is an analytical technique widely employed for separating and purifying biomolecules, pharmaceuticals, and chemical compounds. It operates under lower pressure than high-performance liquid chromatography (HPLC), making it suitable for tasks where high-resolution separation is less critical and cost efficiency is prioritized. Due to its simpler operation and minimal requirement for sophisticated equipment, LPLC has found applications across research labs, pharmaceutical industries, and biochemical processing. LPLC systems typically leverage gravity flow or low-pressure pumps, providing a controlled environment for sample separation without compromising the integrity of delicate compounds, which is particularly valuable in protein purification and extraction processes.

The Low-Pressure Liquid Chromatography Market Size was valued at USD 7.25 billion in 2023 and is expected to reach USD 13.72 billion by 2032 and grow at a CAGR of 7.36% over the forecast period 2024-2032.

Future Scope

The future of low-pressure liquid chromatography appears promising as new advancements are emerging to enhance its efficiency, affordability, and application scope. With innovations in column design and stationary phases, LPLC is evolving to deliver higher separation precision and faster run times. As demand for cost-effective solutions rises, especially in developing regions, LPLC is positioned as a preferred choice for small-to-medium-scale purification tasks. Furthermore, the technique is likely to benefit from advancements in automation and digital monitoring, which could improve reproducibility and facilitate remote operation. These advancements are expected to increase its use in the pharmaceutical and academic research sectors, particularly for preparative purposes, thereby expanding LPLC’s utility in the global analytical instrumentation market.

Trends

Recent trends in low-pressure liquid chromatography highlight a move towards more specialized applications, such as purifying biopharmaceuticals and isolating natural products. Researchers are increasingly turning to eco-friendly solvent systems and biodegradable materials in chromatography columns to support green chemistry initiatives. Additionally, miniaturized and portable LPLC systems are gaining traction as they offer enhanced mobility and convenience, particularly for on-site testing in environmental and food safety applications. The integration of LPLC with other analytical techniques, such as mass spectrometry and spectrophotometry, has also become popular, offering enhanced analytical capabilities and comprehensive data collection. As a result, these trends are enabling more robust applications across a broader range of sectors.

Applications

Low-pressure liquid chromatography is a versatile tool used in numerous fields for various applications. In the biopharmaceutical industry, it aids in the purification of proteins, antibodies, and other biomolecules, ensuring the production of highly pure compounds needed for drug development. In academic and industrial research, LPLC is essential for fractionating complex mixtures, allowing researchers to isolate specific compounds of interest. The technique is also extensively used in environmental monitoring, where it helps in the analysis and separation of organic pollutants and toxins from water samples. Additionally, LPLC finds applications in the food and beverage industry for quality control and in natural product research to isolate plant-derived compounds. These diverse applications underscore the method's adaptability and effectiveness across multiple sectors.

Key Points

LPLC operates at lower pressures, making it ideal for cost-effective and preparative separation applications.

It is commonly used in protein and biomolecule purification, with significant applications in pharmaceuticals.

Growing adoption of green chemistry practices has influenced the development of eco-friendly solvents and materials in LPLC.

Miniaturized LPLC systems are emerging to meet demands for portable, on-site analysis in environmental and food safety testing.

Integration with other analytical methods, like mass spectrometry, enhances LPLC’s analytical power and data accuracy.

LPLC is instrumental in isolating and studying plant-based compounds, aiding research in natural products and pharmacognosy.

Conclusion

Low-pressure liquid chromatography is solidifying its role as an accessible, reliable, and adaptable tool across numerous industries. With advancements in automation and eco-friendly materials, as well as trends towards portable devices, LPLC is becoming more efficient and versatile. As the technique continues to evolve, its relevance in sectors like biopharmaceuticals, environmental testing, and natural product research is only expected to grow, making it an essential tool for modern laboratories. LPLC’s continued development and integration with other analytical techniques ensure it will remain an invaluable asset for separation and purification tasks, supporting critical research and development efforts in the years ahead.